FFG Partners LLC Takes Position in Novo Nordisk A/S $NVO

FFG Partners LLC bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 67,501 shares of the company’s stock, valued at approximately $2,481,000. Novo Nordisk A/S comprises about 1.0% of FFG Partners LLC’s holdings, making the stock its 22nd largest position.

Several other institutional investors have also bought and sold shares of the stock. Franklin Resources Inc. boosted its holdings in Novo Nordisk A/S by 4,190.8% during the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after acquiring an additional 13,658,867 shares during the last quarter. Capital International Investors grew its stake in shares of Novo Nordisk A/S by 52.4% in the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after acquiring an additional 6,092,192 shares in the last quarter. Boston Partners purchased a new stake in shares of Novo Nordisk A/S in the third quarter valued at about $310,199,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Novo Nordisk A/S by 99.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after purchasing an additional 4,836,285 shares during the last quarter. Finally, Voloridge Investment Management LLC lifted its position in shares of Novo Nordisk A/S by 851.6% during the fourth quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock valued at $244,594,000 after purchasing an additional 4,302,126 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s oral Wegovy is gaining attention after UK approval, a development that could expand access to its weight-loss treatment and strengthen its position in the fast-growing GLP-1 market. Novo Nordisk (NVO) Stock Surges 6.55% on Oral Wegovy UK Approval
• Positive Sentiment: A South Africa court barred a pharmacy group from selling compounded semaglutide products, which may help Novo Nordisk protect demand for its branded Ozempic and related GLP-1 medicines. South Africa court bars iDexis from selling compounded Ozempic in Novo Nordisk case
• Positive Sentiment: Analyst-style coverage highlighted Novo Nordisk as a leading longevity and anti-aging stock, reinforcing investor optimism around long-term demand for its obesity and diabetes portfolio. Here is why Novo Nordisk A/S (NVO) is among the Best Longevity and Anti-Aging Stocks to Buy
• Neutral Sentiment: A separate article noted Novo Nordisk shares have been volatile this year; while the stock has recovered recently, the company still faces a large gap between the current share price and some long-term valuation estimates. A Look at Novo Nordisk AS (NVO) After 6.2% Gain — GF Value $144.58 vs Price $45.88
• Negative Sentiment: Novo Nordisk is also dealing with a reported data breach investigation, which could raise operational, legal, and reputational risks if sensitive research or trial information was compromised. Novo Nordisk Data Breach: Hackers Claim To Have Stolen Drug Research, Trial Data And AI Models
• Negative Sentiment: Commentary on Novo Nordisk’s Wegovy pill also emphasized a more complicated competitive picture, suggesting rivals may still challenge the company’s market share despite strong launch momentum. Novo Nordisk’s Wegovy pill headlines mask complicated competitive reality

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $45.90 on Tuesday. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $71.79. The stock’s 50-day simple moving average is $43.09 and its 200 day simple moving average is $45.82. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The stock has a market capitalization of $204.94 billion, a price-to-earnings ratio of 10.77, a price-to-earnings-growth ratio of 3.86 and a beta of 0.78.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The business had revenue of $10.85 billion during the quarter. Research analysts forecast that Novo Nordisk A/S will post 3.45 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday. Finally, TD Cowen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target on the stock. in a report on Tuesday, March 10th. Five investment analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.